ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhaojuan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, Qingdao Key Technology Research and Industrialization Demonstration Projects.
Abstract (Originalsprache)
Pancreatic cancer driven by the KRASG12D mutation faces therapeutic challenges from KRAS undruggability and acquired resistance to inhibitors like MRTX1133 via secondary mutations (e.g., Q95/Y96). Here, we report ZJK-807, a novel cereblon (CRBN)-based proteolysis-targeting chimera (PROTAC), conjugating a KRASG12D inhibitor to a CRBN ligand. It selectively degrades KRASG12D (DC50 = 79.5 ± 5.4 nM in AsPC-1 cells) with minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. Critically, ZJK-807 overcomes secondary mutation resistance by degrading mutant KRASG12D and suppressing resistant cell growth where MRTX1133 fails. Transcriptomic analysis revealed that ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis, suggesting distinct mechanistic advantages. In vivo, ZJK-807 (30 mg/kg, subcutaneous) achieved 47% tumor growth inhibition in AsPC-1 xenografts with favorable pharmacokinetics. This study presents a CRBN-based PROTAC to selectively target and degrade resistant KRASG12D mutants, establishing a groundbreaking approach for KRAS-driven malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
- Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong 266071, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, Shandong 266137, China.
ORCID-Profile: Siqi Zhang, Xiao Wang, Chong Qin
Förderung
- Key Technology Research and Development Program of Shandong Province
- Qingdao Key Technology Research and Industrialization Demonstration Projects
Zitieren
APA
Liu, Z., Zheng, H., Tian, Y., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2025). ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01034
Vancouver
Liu Z, Zheng H, Tian Y, Li Z, Zhang S, Zhang S, et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01034
BibTeX
@article{Liu2025,
author = {Liu, Zhaojuan and Zheng, Heping and Tian, Yanqing and Li, Zhuoyue and Zhang, Sai and Zhang, Siqi and Ma, Shumin and Wang, Xiao and Qin, Chong},
title = {ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01034}
}
EUVIMED